Skip to main content

William Zamboni Lab


Dr. Zamboni is an expert in translational studies of anticancer agents. The Zamboni lab, in the Genetic Medicine Research Building, is a drug development and clinical pharmacology lab that focuses on the translational development of drugs, anticancer agents, and nanoparticles. Dr. Zamboni also supervises the Good Laboratory Practice Analytical Facility in Kerr Hall, which supports the development of newly discovered drugs and medical testing procedures.



The goals of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Laboratory in the Genetic Medicine Building are to use analytical chemistry and pharmacologic infrastructure, methodologies and expertise to support the translational development of small molecule, nanoparticle, and biological anticancer agents. The lab develops and validates analytical assays from biological matrices, analyzes samples, performs pharmacokinetic (PK) and pharmacodynamic (PD) analyses of data and provides specialized methods to evaluate the pharmacology of carrier-mediated agents (e.g. nanoparticle, conjugates, antibody drug conjugates). Increased demand for applied pharmacology services have been created by the expansion of the Molecular Therapeutics Program, development of preclinical models to evaluate anticancer agents, and opening of the new North Carolina Cancer Hospital’s (NCCH) Clinical Trials Unit (CTU).  Our lab’s capabilities expand research horizons and funding by providing state of the art support for sample analysis and performing pharmacology studies, and for developing novel methods to meet the needs for sample information.

Examples of this work includes:

1. A series of studies on the development of Particle Replication in Nonwetting Templates (PRINT®) nanoparticles in collaboration with Dr. DeSimone;

  • Merkel TJ, Chen K, Jones SW, Pandya AA, Tian S, Napier ME, Zamboni WE, DeSimone JM. The effect of particle size on the biodistribution of low-modulus hydrogel PRINT particles. J Control Release. 2012 Aug 20;162(1):37-44.
  • Chu KS, Hasan W, Rawal S, Walsh MD, Enlow EM, Luft JC, Bridges AS, Kuijer JL, Napier ME, Zamboni WC, DeSimone JM. Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine. 2013 Jul;9(5):686-93.
  • Sambade M, Deal A, Schorzman A, Luft JC, Bowerman C, Chu K, Karginova O, Swearingen AV, Zamboni W, DeSimone J, Anders CK. Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases. Nanomedicine (Lond). 2016 Aug;11(15):1947-55.
  • Bowerman CJ, Byrne JD, Chu KS, Schorzman AN, Keeler AW, Sherwood CA, Perry JL, Luft JC, Darr DB, Deal AM, Napier ME, Zamboni WC, Sharpless NE, Perou CM, DeSimone JM. Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer. Nano Lett. 2017 Jan 11;17(1):242-248.

2. Local iontophoretic (IO) administration of cytotoxic therapies to solid tumors in collaboration with Dr. Yeh and DeSimone;

  • Byrne JD, Jajja MR, O’Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM. Local iontophoretic administration of cytotoxic therapies to solid tumors. Sci Transl Med. 2015 Feb 4;7(273):273ra14.
  • Byrne JD, Jajja MR, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2200-5.

3. The evaluation of nanoparticle treatment of intracranial malignancies with Dr. Anders.

  • Anders CK, Adamo B, Karginova O, Deal AM, Rawal S, Darr D, Schorzman A, Santos C, Bash R, Kafri T, Carey L, Miller CR, Perou CM, Sharpless N, Zamboni WC. Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS One. 2013 May 1;8(5):e61359.
  • Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O’Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, Lee YZ, Miller CR, Anders CK. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 Apr;14(4):920-30.

Example of previously funded grants and studies includes:

  • Pre-clinical Studies of Targeted Nanoparticle Delivery Agents
  • Studies Evaluating Measures of the Reticuloendothelial System as Predictors of Doxil Pharmacokinetic and Pharmacodynamic Disposition in Patients with Refractory Ovarian Cancer, sponsored by the University Cancer Research Fund (UCRF) and Carolina Center for Cancer Nanotechnology Excellence (C-CCNE) Pilot Grant
  • Study evaluating Relationship between Mononuclear Phagocytic System in Tumors and Tumor Delivery and Efficacy of Nanoparticle Anticancer Agents in Genetically Engineered Mouse Models of Breast Cancer, sponsored by NC Translational and Clinical Sciences Institute
  • Precision Engineering of Ultrasonically-Targeted Drug Delivery Vehicles, sponsored by NC State University.
  • A New Dimension in Renal Clearance Design Criteria for Dendrimer Nanostructures, sponsored by NIH/NIDDKD.
  • Organismal and Genetic Networks in Drug Reward and Reinforcement, sponsored by NIH.
  • STTR Phase II Grant: Blockage of NF-Kappa B for Prevention/Treatment of GVHD, sponsored by NIH/NCI P42 Grant.
  • Evaluating the Role of Genotype in Tamoxifen Therapy for Breast Cancer, sponsored by UNC Hospitals.
  • A Two Arm Phase I Study of Sorafenib with Carboplatin/Pemetrexed and Cisplatin/Etoposide, sponsored by UNC Hospitals.
  • Phase I study utilizing an intravenous busulfan test dose to prospectively target and determine the maximum tolerated systemic exposure (MTSE) of a continuous intravenous infusion of busulfan, sponsored by UNC Hospitals.
  • Evaluating the Effect of Aprepitant on Cyclophosphamide Pharmacokinetics, sponsored by UNC Hospitals.

  • Solid phase separation of encapsulated and released fractions of novel nanoparticle agents in samples: Dr. Zamboni’s lab has developed a solid phase separation (SPS) method that differentiates the inactive nano-carrier encapsulate and the active ‘released’ forms of many common nanomedicines. This process can be applied to any solution or plasma sample and combined with an instrumental assay to determine concentrations of encapsulated, released, and total drug in a given sample. SPS has been used in the lab to separate the encapsulated and released forms of nano-formulations of platinum analogues, camptothecins, taxanes, and anthracyclines, as well as liposomal topotecan and pegylated liposomal doxorubicin (PLD/Doxil).  These are the only known sample processing methods that can directly measure the encapsulated and released forms of a nanomedicine agent.
  • Biological sample processing: The lab is proficient in sample processing development for novel nano agents in tumor, tissues, and plasma and other fluids. Processing can involve centrifugation, liquid/liquid extraction, evaporation and reconstituting in solvent, solid phase extraction, or a combination of these and other techniques.
  • HPLC or LC-MS/MS analysis: Capabilities include high performance liquid chromatography (HPLC) with fluorescence detection (all HPLC equipment by Shimadzu) and HPLC coupled with mass spectrometry (MS). MS capabilities available include triple quad fragmentation analysis (Thermo Quantum Ultra LC-MS/MS), orbitrap full scan analysis for very high resolution and mass accuracy (Thermo Exactive LC-MS), and a hybrid orbitrap-linear ion trap instrument that combines the strengths of both triple quad and orbitrap analysis (Thermo LTQ Orbitrap Discovery).
    • Determination and verification of physico-chemical properties
    • Validation of chemical composition, molecular structure and mass
    • Qualitative and quantitative detection
  • Development of in vivo pharmacokinetic and pharmacodynamic studies: The lab has extensive experience evaluating the ADME, pharmacokinetic, toxicology, and efficacy of nano-carrier and non-nano-carrier anticancer agents in preclinical models.  This includes the development of sampling strategies and schedules, sampling processing methods, and analytical assays for ADME and pharmacokinetic studies of nano agents in blood, plasma, tissues, tumor, urine, and bile. The lab works closely with university animal facilities for study management and harvesting and has access to an animal facility within the same building. The Animal Studies Core, affiliated with the UNC Lineberger Comprehensive Cancer Center, provides full access to a range of cancer cell lines and animal models, including genetically modified mouse models of human cancers. Consultation is available for assistance with or management of study design and data analysis.
  • Pharmacokinetic/pharmacodynamic analysis (PK/PD) :Data collected at multiple timepoints after the administration of a nanomedicine in animal models allows for a complete pharmacokinetic and pharmacodynamic analysis of the nano agent in vivo. PK/PD assessments are performed using WinNonlin data management, a statistics, modeling, and visualization tool for PK data analysis. Parameters typically provided for a given nanomedicine include drug concentration over time, area under the curve (AUC), elimination half life, clearance, and time of maximum concentration.
  • Efficacy studies: Studies may be designed that will evaluate a nano agent’s effects in vivo over an extended period of time (usually several weeks). Dose administration at one or several timepoints can be used to evaluate overall toxicity in the animal model and any effects on tumor cells and growth. Efficacy can be measured via survival rate, tumor growth, and quantitative analysis of drug in the tumor.
  • Pheno-GLO High-throughput Screening Platform (HTSP): Preliminary studies by the lab suggest that the pharmacokinetic and pharmacodynamic disposition of nanomedicines is related to the function of the immune system, particularly the monocytes and dendritic cells of the mononuclear phagocyte system (MPS). These cells, as well as tissue macrophages, located primarily in the liver and spleen, lymph nodes and general circulation, serve as a potential clearance pathway for nanoparticles. Pheno-GLO HTSP is a process developed internally that uses cellular function assays and flow cytometry to evaluate the relationship between nano agents and the MPS. This relationship can indicate the activity and level of stimulation that a given nanomedicine may have within the immune system.  Profiling these interactions builds upon information gained from initial physico-chemical measurements to provide a clearer picture of a nanomedicine’s behavior as defined by its properties.

The following analytical assays are available to be performed by the Zamboni lab:

GLP  validated:

  • Docetaxel – total and protein unbound
  • Irinotecan (CPT-11)
  • SN-38
  • DTPA and C2E5

Non-GLP validated:

  • Docetaxel
  • Paclitaxel
  • nab-paclitaxel (Abraxane)
  • Irinotecan (CPT-11)
  • SN-38 and glucuronidated SN-38 (SN-38G)
  • Camptothecin (CPT)
  • Topotecan
  • Gemcitabine
  • Doxorubicin – total and DNA-bound
  • PEGylated liposomal doxorubicin (e.g. Doxil and Lipodox) – total, encapsulated, released
  • 5-fluorouracil
  • Carboplatin – total and protein unbound
  • Cisplatin – total and protein unbound
  • Oxaliplatin – total and protein unbound
  • Curcumin
  • Cocaine and metabolites

Instrumentation in the Zamboni Lab

  •  Shimazdu 20 series High Performance Liquid Chromatograph (HPLC) systems with fluorescence detection
  • Thermo TSQ Quantum Ultra triple quad Mass Spectrometer with attached Shimazdu 20 series HPLC
  • Thermo TSQ Quantum Access triple quad Mass Spectrometer with attached Shimadzu 10 series HPLC
  • Thermo LTQ Orbitrap Discovery Fourier Transform orbitrap/ion trap Mass Spectrometer with attached Shimazdu 20 series HPLC
  • Thermo Exactive orbitrap Mass Spectrometer with attached Shimazdu 20 series HPLC
  • Agilent 7700 Inductively-Coupled Plasma Mass Spectrometer (ICP-MS)

William Zamboni

(919) 843-6665

William Zamboni, Pharm.D., Ph.D., is an associate professor in the Division of Pharmacotherapy and Experimental Therapeutics and UNC Lineberger Comprehensive Cancer Center. He is the director of UNC GLP Bioanalytical Facility and the director of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab. His research interests focus on the application of pharmacokinetic, pharmacodynamic, and pharmacogenetic principles in the optimization of the chemotherapeutic treatment of cancer.

My research program is part of the Division of Pharmacotherapy and Experimental Therapeutics (DPET) in the Eshelman School of Pharmacy at the University of North Carolina (UNC) and the UNC Lineberger Comprehensive Cancer Center (LCCC).  I have been involved in translational studies of anticancer agents for several years.  My research interests focus on the application of pharmacokinetic, pharmacodynamic, and pharmacogenetic principles in the optimization of the chemotherapeutic treatment of cancer. Information obtained from preclinical and clinical translational studies can greatly add to the understanding of the pharmacology of anticancer agents, permit individualization of chemotherapeutic treatment based on pharmacokinetic, pharmacodynamic, and pharmacogenetic principles, and allow for the rational design of therapeutic regimens.

A second focus of my research is on the development of liposomal and nanoparticle anticancer agents and evaluating the relationship between the disposition of these agents and the mononuclear phagocyte (or reticuloendothelial) system.  As part of these studies, I have used microdialysis to evaluate the tumor extracellular fluid disposition of anticancer agents and factors affecting the delivery and removal of anticancer agents.  I have also developed methods and technologies to differentiate between the inactive-encapsulated and active-released forms of nanoparticles drugs.  We are evaluating potential phenotypic probes for the pharmacokinetic and pharmacodynamic disposition of liposomal and nanoparticle agents.  The clinical relevance of studies is underscored by the need to treat solid tumors using anticancer agents with high tumor penetration, develop methods to increase the tumor delivery of liposomal and nanoparticle agents, and generate administration schedules to enhance selective tumor uptake.

Andrew Lucas

(919) 966-5242

Dr. Lucas, Pharm.D., M.S. is an assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics and has been involved in cancer research for over 11 years, and translational/clinical studies of anti-cancer agents for greater than 7 years. His translational research program focuses on how functional variations in innate immunity can lead to differences in the pharmacokinetics and pharmacodynamics of therapeutic treatments with high inter-patient variability used in oncology (such as monoclonal antibodies or drug conjugates). In addition, he has been highly trained to perform the detailed analytical and pharmacology studies required for the translational development of targeted agents.


Kristy Ainslie

(919) 962-4556

Kristy Ainslie, Ph.D. applies her knowledge base in biomaterials, and immunology to develop new immune-modulatory therapies that treat and prevent infectious, and autoimmune diseases. Her lab aims to design practical and innovative formulations, taking into account the scalable production and applications in developing nations.

Amir Alishahi Tabriz

(919) 966-7642

Amir Alishahi Tabriz, MD, MPH, PhD is a Post-doctoral Research Associate in the Division of Pharmaceutical Outcomes and Policy at the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. He is an ER physician by training. His main area of research and interest is the intersection between emergency department operations and implementation science with a focus on cancer care delivery.

Heidi Noel Anksorus

(919) 843-2583

After receiving her Pharm.D. from the University of Illinois at Chicago, Heidi Anksorus completed a PGY-1 pharmacy practice residency at St. Joseph Regional Medical Center in South Bend, Indiana. Upon completion of the residency, she was offered a position with St. Joseph, where she continued developing as a new practitioner while working in various areas of the medical center’s inpatient and clinical pharmacy services, as well as working in the community pharmacy practice setting.

Aaron Anselmo

(919) 966-1126

The Anselmo lab focuses on understanding microbe-material-host tissue interactions to develop: (i) formulations for the improved delivery of therapeutic microbes, (ii) materials-based in vitro culture approaches to enable the co-culture of microbial ecologies alongside mammalian cells, and (iii) targeted approaches for the delivery of therapeutic microbes.

Lori Armistead

(919) 536-2737

Lori T. Armistead, Pharm.D., joined the Center for Medication Optimization as a senior research associate in September 2016. Armistead holds a master’s degree in chemistry from UNC Chapel Hill and earned her Doctor of Pharmacy from the UNC Eshelman School of Pharmacy. She subsequently completed a pharmacy residency in ambulatory care pharmacy practice at UNC Hospitals and Clinics. Her professional interests focus on improving medication access and adherence for patients with chronic medical conditions.

Mohamed Attia

(919) 962-1011

Dr. Attia joined the CCNTP at the laboratory of Alexander Kabanov in 2020. He received his B.S. and M.S. degrees in chemistry from Sohag University and Cairo University, Egypt, respectively. He earned his Ph.D. in pharmaceutical chemistry from Strasbourg University, France in 2016. He then joined both the bioengineering and chemistry departments in Clemson University as a postdoc research associate. Most recently, two press releases have been issued and posted on Clemson newsstand about his work and winning the 2020 Clemson University distinguished postdoc award. He served as a guest editor for a special issue “Polymers for Biomedical Imaging and Therapy” in Polymers, MDPI. The central theme of his research, in cancer nanomedicine, aims to design smart vectors (i.e., polymer, lipid, and inorganic nanomaterials) to deliver a wide range of therapeutic/contrast agents and targeting moieties, and to fabricate multifunctional nanoparticles for combinatory therapy and theranostic applications using cutting edge technologies. His long-term research career is to facilitate the translation of nanoparticle-based therapeutics from the lab to the clinic.

Jeff Aubé

(919) 966-9650

ACCEPTING DOCTORAL STUDENTS The Aubé laboratory uses synthetic chemistry to enable the study of biological pathways and as starting points for drug discovery. Current efforts in the group include the study of new opioids lacking side effects, new approaches for the treatment of tuberculosis, androgen biosynthesis inhibitor discovery, the search for RNA-protein interaction inhibitors, and the development of new synthetic methods.

Alison Axtman

(216) 470-7201

Axtman is currently a research assistant professor in the Chemical Biology and Medicinal Chemistry Department in the UNC Eshelman School of Pharmacy. At the SGC-UNC, she leads the design of novel chemical probes for understudied protein kinases that will be openly shared with collaborators to facilitate target discovery in human disease-relevant assays. When she’s not in the lab, Axtman can most often be found at the gym preparing for the next CrossFit or GRID competition with her teammates.

Eric Michael Bachelder

Bachelder focuses on the development of biomaterials for the treatment of diseases associated with the immune system, inlcuding using liposomes, acid sensitive polymers, and tissue engineering scaffolds.

Edward Moreira Bahnson

(919) 843-0842

Bahnson’s interest in diabetic vasculopathies is two-fold: understanding the difference in plaque progression and restenosis rates in the diabetic vs. non-diabetic environment. Atherosclerosis leading to CVD and PAD is a leading cause of morbidity and mortality in diabetic patients. It is paramount to gain insight into the particular diabetic milieu that so profoundly affects the progression of atherosclerotic disease and the rates of restenosis after revascularization.

John Bamforth, PhD

(919) 966-7878

John Bamforth, Ph.D., is the director of the Eshelman Institute for Innovation at the UNC Eshelman School of Pharmacy. The Eshelman Institute for Innovation was established in 2014 with a $100 million gift from Dr. Fred Eshelman. The Institute aims to accelerate the creation and development of ideas leading to discoveries of new medicines and technologies, and transformative changes in pharmacy/pharmaceutical sciences education and health care. Bamforth will vigorously pursue the mission and goals of the Institute, while developing new strategies to put the Institute on a path to sustained growth. Bamforth comes to the School after almost 30 years with Eli Lilly and Company. In his most recent role at Lilly, he served as the vice president and chief marketing officer for a broad portfolio including products for cardiovascular, immunological, pain and neuro-degenerative disorders. Bamforth completed his Bachelor of Pharmacy at the University of Bath in Bath, England; and earned his Ph.D. at Aston University in Birmingham, England.

Amy Barrett

Amy Barrett, MA, MSPH, is a PhD student in the Division of Pharmaceutical Outcomes and Policy at the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill.

Elena V Batrakova

(919) 537-3712

The main focus of Batrakova’s research is to develop a CNS delivery system for antioxidants and neuronal growth factors to attenuate neuroinflammation and produce neuroprotection in patients with neurodegenerative disorders, such as Parkinson’s and Alzheimer’s diseases. For this purpose, her group utilizes inflammatory-response cells, macrophages and monocytes that can migrate toward the inflammation site, cross the blood brain barrier, and release the preloaded drugs in the brain.

James John Beaudoin

(919) 966-5709

James Beaudoin, M.S., is a graduate student in the Division of Pharmacotherapy and Experimental Therapeutics. His research interests include personalized drug therapy, pharmacometrics, drug toxicity, drug metabolism and drug transport.

Jessica Beers

(919) 999-9999

Jessica obtained her bachelor’s degree in chemistry from the University of Tennessee at Chattanooga and her PharmD from Lipscomb University College of Pharmacy. She is currently pursuing a PhD in the Division of Pharmacotherapy and Experimental Therapeutics in the laboratory of Dr. Klarissa Jackson at UNC Eshelman School of Pharmacy. Jessica is studying the genetic and metabolic factors that influence adverse drug reactions and the role of drug metabolism and transport in informing pharmacokinetic models. Her current project focuses on characterizing the metabolism, transport, and hepatotoxicity of cannabidiol (CBD), a popular consumer product derived from Cannabis sativa that was recently FDA-approved to treat rare and severe forms of epilepsy in children. She is also interested in identifying possible pharmacogenomic differences in drug metabolizing enzymes that may influence CBD metabolism and subsequent toxicity.

Soumya Benhabbour

(919) 843-6142

Dr. Benhabbour’s research focuses on the development of novel delivery platforms and polymer-based devices that can treat or prevent a disease. Her work combines the elegance of polymer chemistry with the versatility of engineering and formulation development to design and fabricate efficient and translational delivery systems for HIV prevention and cancer treatment. The current limitations in drug delivery such as rapid drug release and limited efficacy are opportunities for breakthrough science that will impact human health. In particular, the greatest impact of Dr. Benhabbour’s technologies for HIV prevention could be in women in sub-Saharan Africa, where approximately 10,000 women are infected with HIV every day.

Susan Blalock

(919) 962-0080

Susan Blalock, Ph.D., M.P.H., is a professor in the Division of Pharmaceutical Outcomes and Policy. She is a behavioral scientist with expertise in the area of patient and public health education and is particularly interested in risk communication and the impact of pharmaceutical care, including patient education and counseling, on patient health outcomes.

Carrie Martin Blanchard

(919) 966-9978

Carrie Martin Blanchard, PharmD, MPH joined the Center for Medication Optimization in May 2018 as a research assistant professor and lead of education and research development. She holds her Masters of Public Health in Health Policy and Management from the UNC Gillings School of Global Public Health and earned her Doctor of Pharmacy from the UNC Eshelman School of Pharmacy. She subsequently completed a two-year Postdoctoral Research Fellowship in Implementation Science at the UNC Eshelman School of Pharmacy in partnership with the National Implementation Research Network. Her research interests focus on how to implement and scale medication optimization services and value-based care models.

Albert Bowers


ACCEPTING DOCTORAL STUDENTS Albert Bowers received his PhD in organic chemistry (synthetic methods) from the University of Illinois at Chicago. He carried out postdoctoral research (total synthesis) at Colorado State University before moving as an NIH sponsored fellow to Harvard Medical School (biosynthesis). He is a member of the UNC Lineberger Comprehensive Cancer Center and affiliate member of the Center for Integrative Chemical Biology and Drug Discovery.

Laura H Bratsch

(919) 966-7658

Coordinates, manages, and leads all administrative operations for the Office of Global Engagement. Responsibilities include overseeing budgetary and finance operations; supervising student workers and student ambassadors along with Office of Global Engagement events.

Kim L. R. Brouwer

(919) 962-7030

Kim L.R. Brouwer, Pharm.D., Ph.D., is the William R. Kenan Jr. Distinguished Professor in the Division of Pharmacotherapy and Experimental Therapeutics of the UNC Eshelman School of Pharmacy, associate dean for research and graduate education, and a professor in the curriculum in toxicology.

Patrick Brown

(919) 966-9124

Patrick Brown, PharmD is Clinical Programs Coordinator at Mutual Drug Company, and Assistant Professor of Clinical Education in the Division of Practice Advancement and Clinical Education at the UNC Eshelman School of Pharmacy.

Yevgeny Brudno

(919) 966-1901

Yevgeny Brudno is faculty at the Joint Biomedical Engineering Department at UNC-Chapel Hill and NCSU-Raleigh. Research in the Brudno lab focuses on exploiting cutting-edge chemical, biomaterial and nanomedicine technologies to understand physiological responses during disease and regeneration and fulfill critical unmet needs in the clinic. His group will use chemical prodrug therapy, controlled drug delivery and nanomedicine to enable new forms of cancer chemotherapy and immunotherapy as well as treatment of infection and other diseases.

Paul Bush

Paul Bush is the Vice President for Global Resource Development and Consulting for the American Society of Health-System Pharmacists (ASHP).  He has held the positions of Chief Pharmacy Officer for Duke University Hospital in Durham, NC, Director of Pharmacy Services for Medical University of South Carolina, St. John Hospital and Medical Center and Detroit Osteopathic Hospital and was Corporate Director for Clinical Pharmacy Services for Horizon Health System.

Yanguang Cao

(919) 966-4040

Yanguang Cao, Ph.D., joined the UNC Eshelman School of Pharmacy as an assistant professor in the division of Pharmacotherapy and Experimental Therapeutics. He received his Ph.D. at China Pharmaceutical University. Prior to joining the School, Cao served as a research assistant professor at SUNY Buffalo for two years after completing a postdoctoral training program at SUNY, Buffalo.

Amy Cardenas

(919) 962-8616

Amy Cardenas, M.A., is a public health researcher with twenty years of experience. She has expertise in advanced qualitative data analysis and data collection. She is highly skilled in the planning and implementation of public health projects. Ms. Cardenas has collected data, conducted assessments, and analyzed data for projects on health, program evaluation, HIV, substance abuse, and homelessness. In September of 2019, Ms. Cardenas joined the Center for Medication Optimization (CMO) as a Senior Research Associate.

Delesha Miller Carpenter

(828) 250-3916

Delesha Carpenter, PhD, MSPH, is an associate professor and Interim Chair in the Division of Pharmaceutical Outcomes and Policy. Her research focuses on developing trainings to improve patient-provider communication about sensitive issues, like suicide and substance abuse use disorders. She also runs an active research program in inhaler technique education and mHealth. She is especially interested in improving access to healthcare services in rural areas and directs a practice-based research network for rural community pharmacists.

Susan Charamut

(919) 962-5382

Susan Charamut received her BS in Accounting from Saint Thomas Aquinas College in New York. Susan is a former CPA who began her career as an auditor with what was then a “big eight” accounting firm, Price Waterhouse. She has worked in healthcare finance, elementary education, an investment firm and public health. As CIPhER’s Center Administrator, she provides comprehensive center and program management.

Hui-Han Chen

Hui-Han Chen received his MHS degree in Health Economics from Johns Hopkins Bloomberg School of Public Health with particular interests in economic evaluation, pharmacoeconomics, and the role health economists can contribute to increasing the efficiency, affordability, as well as equity of medications. Hui-Han went to the National Taiwan University (NTU) where he holds his BS in Pharmacy. After graduating from NTU, he worked as a hospital pharmacist in National Taiwan University Hospital for three years.

Karen Chen

(999) 999-9999

Karen Chen is an undergraduate student studying pre-pharmacy at the University of North Carolina at Chapel Hill. She serves as a Center Assistant in CIPhER where she supports administrative functions for CIPhER programming.

Rachel Church

(919) 244-4085

Rachel Church, PhD, is a research assistant professor within the Division of Pharmacotherapy and Experimental Therapeutics and the Director of the Organ Injury Biomarker Core within the UNC Institute for Drug Safety Sciences. Dr. Church’s has expertise in identifying and characterizing novel translational biomarkers of drug-induced organ injury, especially drug-induced liver injury, and developing innovative methodologies to maximize the utility of traditional biomarkers.

Amber Cipriani

(919) 966-4882

Amber Cipriani, Pharm.D., joined the UNC Eshelman School of Pharmacy as a clinical assistant professor in the Division of Pharmacotherapy and Experimental Therapy. Proctor’s appointment is cofunded by UNC Hospitals, where she serves as a clinical oncology specialist in thoracic oncology.

Kelly Mansfield Collins

(919) 966-1963

Kelly Collins is associate dean of advancement for the UNC Eshelman School of Pharmacy and president of the UNC Eshelman School of Pharmacy Foundation. She also serves as executive director of the Pharmacy Alumni Association and chief development officer for the Eshelman Institute for Innovation. Previously Kelly served as assistant dean of development leading the School’s fundraising activity in the Campaign for Carolina. In 2021, the School surpassed its $175 million campaign goal 20 months early. Prior to joining the School of Pharmacy, Kelly worked at the UNC Lineberger Comprehensive Cancer Center as director of development. Her previous work experience spans academic medical development, communication strategy and business.

Amanda Corbett

(919) 843-2280

Amanda Corbett, Pharm.D., is an associate professor in the Division of Pharmacotherapy and Experimental Therapeutics and the Global Pharmacology Coordinator for the UNC Institute of Global Health and Infectious Diseases. Her expertise are in HIV, antiviral, and opportunistic infection clinical pharmacy and ethnopharmacology. She has extensive experience in developing countries and more recently in integrative medicine practices.

Carla Coste Sánchez

Carla Coste Sánchez, PhD, is a postdoctoral research associate with CIPhER at the UNC Eshelman School of Pharmacy. She received her undergraduate degree in chemistry from the University of Puerto Rico – Rio Piedras, and her PhD in Pharmaceutical Sciences (Pharmacoengineering and Molecular Pharmaceutics) from the University of North Carolina – Chapel Hill. Her research interest include: best practices in teaching, curriculum development and assessment practices and professional development in graduate school education.

Mackenzie Leigh Cottrell

Mackenzie Cottrell, Pharm.D., M.S. is an assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics. Her research focuses on describing pharmacokinetic/pharmacodynamic relationships in mucosal tissues for antiretrovirals being used in HIV prevention and cure interventions.

Wendy Cox

(919) 966-9990

Wendy Cox, PharmD, is associate dean for professional education and a clinical associate professor in the Division of Practice Advancement and Clinical Education at the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. Cox received her Doctor of Pharmacy from the UNC Eshelman School of Pharmacy. After graduation, she completed a pharmacy practice residency at the Medical University of South Carolina and a primary care specialty residency affiliated with Campbell University at Kaiser Permanente in Cary, NC, and the Southern Regional Area Health Education Center in Fayetteville, NC.

Daniel Crona

(919) 966-4343

Daniel Crona, Pharm.D., Ph.D., joined the UNC Eshelman School of Pharmacy in 2015. His translational research program focuses on how genetic variations can lead to differences in the pharmacokinetics and pharmacodynamics of therapeutic treatments used in oncology, and how inter-individual differences in clinical pharmacology measures can affect survival and drug toxicity phenotypes.

Scott Davis

(919) 962-0106

Scott A. Davis, PhD, is a research assistant professor in the Division of Pharmaceutical Outcomes and Policy at the UNC Eshelman School of Pharmacy. His research focuses on pragmatic clinical trials testing interventions to improve patients’ use of medications to achieve optimal real-world outcomes, as well as implementation and dissemination of these interventions. Following graduation from the DPOP PhD program in 2018 as a Royster Fellow, he completed an NC TraCS TL1 MOTRD UP postdoctoral fellowship to gain more intensive training in implementation science and dissemination of successful interventions. This training will allow him to work with providers and health systems to improve the quality of patient education about their medications in clinics and pharmacies, in ways that minimize unnecessary cost and time burden to providers and staff. He also works with faculty at MAHEC to design and evaluate innovative programs for improving patient and caregiver activation and engagement with the healthcare system, particularly in relation to the underserved in rural areas.

Paul Dayton

(919) 843-9521

Prior to joining UNC in 2007, Dayton was research faculty at the University of California at Davis. His research interests currently involve applications of ultrasound imaging for assessment of tissue perfusion and monitoring of response to therapy. Other interests include ultrasound-mediated therapeutic approaches.

Joseph M. DeSimone

(919) 962-2166

The recent breakthroughs in the DeSimone laboratories using specifically-designed materials for imprint or soft lithography have enabled an extremely versatile and flexible method for the direct fabrication and harvesting of monodisperse, shape-specific nano-biomaterials. The method, referred to as Particle Replication In Non-wetting Templates, or PRINT, allows for the fabrication of monodisperse particles with simultaneous control over structure (i.e. shape, size, composition) and function (i.e. cargo, surface structure).

Aaron Devanathan

(919) 966-9429

Aaron Devanathan, PharmD is a graduate student in the Division of Pharmacotherapy and Experimental Therapeutics after having completed residency training at UNC Hospitals. Devanathan is focused on the distribution of antiretroviral drugs within active HIV reservoirs, an area of interest towards a cure. His research aims to visualize, quantify, and model the interspecies pharmacokinetics of antiretroviral therapy within the spleen tissue.

Daysi Diaz-Diestra

(919) 962-1011

Dr. Diaz-Diestra obtained her PhD in Physical Chemistry in 2019 from the University of Puerto Rico-Rio Piedras. Her doctoral research focused on the development of sensing and drug delivery platforms based on functional engineered nanomaterials, and their potential toxic effects on in vitro settings. After graduation, she joined the FDA Center for Devices and Radiological Health as an ORISE postdoctoral research fellow. Her research focused on regulatory control and biocompatibility assessment of nanoformulations used in medical devices.  She joined the CCNTP in December 2020, where she is working under the guidance of Drs. Jenny Ting and Leaf Huang in Nanoparticle-Enabled Cancer Immunotherapy

Matthew Dixon

(919) 966-9429

Matthew Dixon, PharmD, is a PhD candidate in the Division of Pharmaceutical Outcomes and Policy at the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. His research interests include pharmacoepidemiology and pharmacoeconomics in oncology. His dissertation research is focused on understanding how a new diagnosis of cancer effects adherence to antidepressant medications.

David Drewry

(919) 962-5349

ACCEPTING DOCTORAL STUDENTS The Drewry lab in focused on designing, synthesizing, evaluating, and sharing small molecule chemical probes for protein kinases. These tools are used to build a deeper understanding of disease pathways and facilitate identification of important targets for drug discovery. Through wide ranging partnerships with academic and industrial groups, the Drewry lab is building a Kinase Chemogenomic Set (KCGS) that is available to the community for screening.

Julie Dumond

(919) 966-5017

Julie Dumond, Pharm.D., M.S., is an associate professor in the Division of Pharmacotherapy and Experimental Therapeutics. Her primary research interest is the pharmacokinetics/pharmacodynamics of antiretrovirals. She is currently conducting a clinical study in aging, HIV-infected subjects to explore the effects of cellular aging and frailty on antiretroviral toxicity and efficacy.

Robert Dupuis

(919) 966-6194

Robert Dupuis, PharmD, FCCO, is a clinical professor and vice department chair within the Division of Pharmacotherapy and Experimental Therapeutics. Dr. Dupuis is also the division’s director of fellowship programs. In this role, he advises postdoctoral fellows on clinical research in the areas of regulatory affairs, medical affairs, clinical development, and pharmacometrics. Dr. Dupuis has expertise in clinical pharmacology, drug metabolism, drug disposition, pharmacogenomics, adverse effects, outcomes and enhancement of care.

Jon Easter

(919) 962-7515

Jon Easter joined the UNC Eshelman School of Pharmacy in January 2016 as the director of the Center for Medication Optimization and a professor of the practice. The center, which is embedded within the Practice Advancement and Clinical Education Division, seeks to solidify the role of pharmacy practice within new, value based healthcare payment and care delivery models by building a hub to support internal and external collaboration, research and education.

Stephen Eckel

(919) 962-0071

Stephen Eckel, Pharm.D., M.H.A., is associate dean for global engagement and a associate professor in the Division of Practice Advancement and Clinical Education. He leads a two-year Master of Science in Pharmaceutical Sciences with a specialization in health-system pharmacy administration. This degree is hosted at eight hospitals, five of which are in North Carolina and others are located in 3 other states. At UNC Medical Center, he is director of pharmacy for innovation services, where he is residency program director for the 2-year health system pharmacy administration and leadership residency program. He has worked with almost 200 residents over the years.

Samantha Eiffert

Sam started her PhD studies in 2019 in the Pharmacoepidemiology concentration, and is currently conducting simulation and empirical studies on matched cohort designs, as well as on the use and comparative effectiveness/safety of intravenous antibiotics.

Jennifer Elston Lafata

(919) 966-9480

Jennifer Elston Lafata, Ph.D. is Professor and Executive Vice Chair in the Division of Pharmaceutical Outcomes and Policy at the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. She also serves as the co-lead for the UNC Cancer Care Quality Initiative and Associate Director in the UNC Institute for Healthcare Quality Improvement. She conducts practice-integrated research to understand and improve patient-clinician communication and decision making, particularly in the context of cancer prevention and control.

Ruth Everett

(919) 962-0092

Ruth Everett worked for several years as a lecturer and head of the Department of Zoology at Jyoti Nivas College, Bangalore. She gained experience in cell and molecular biology at the Cystic Fibrosis/Pulmonary Research and Treatment Center at UNC-Chapel Hill and at the University of Arkansas for Medical Sciences (Department of Pulmonary Medicine) as a research instructor, She joined the laboratory of Dhiren Thakker initially as a visiting scholar and then as research faculty.

Gang Fang

(919) 966-7517

Gang Fang, Pharm.D., Ph.D., is an associate professor in the Division of Pharmaceutical Outcomes and Policy. His research is centered in the areas of evaluating treatment utilization and outcomes in populations and pharmacoepidemiology especially in cardiovascular disease.

Kyle Fassett, PhD

Kyle Fassett, Ph.D., is a postdoctoral research associate with CIPhER at the UNC Eshelman School of Pharmacy. He received a doctorate in higher education with a focus in educational psychology, measurement, and evaluation and a master’s in learning sciences from Indiana University Bloomington. He also holds a master’s in college student personnel from Bowling Green State University. His research focuses on teaching and learning inside and outside the classroom as well as the experiences of queer collegians.

Stefanie Ferreri

(919) 843-9765

Stefanie Ferreri, Pharm.D., is the Henry L. Smith and James L. Olsen, PhD Distinguished Professor in Pharmacy Practice and Chair of the Division of Practice Advancement and Clinical Education at the UNC Eshelman School of Pharmacy. Her main research interests include advancing clinical practice in the community-pharmacy setting. Through her research, she hopes to change the way community practice is portrayed and delivered to the population of the United States while influencing reimbursement strategies that affect health policy. Her other interests include nonprescription therapeutics, medication therapy management, the pharmacists’ process of patient care and postgraduate training.

Patrice Fleming

(919) 966-1735

Patrice Jordan Fleming, MS is a Research Associate II in the Division of Pharmaceutical Outcomes and Policy at the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. Her research and public health interests center on using community and patient engagement as a means to improve cancer care quality and promote health equity along the cancer care continuum. She is an epidemiologist by training.

Jennifer Ford, Ph.D.

Jennifer Ford is a Postdoctoral Research Associate in the Division of Pharmacotherapy and Experimental Therapeutics at the UNC Eshelman School of Pharmacy working in the Gonzalez lab.

Christopher Fortier

Christopher Fortier is the Chief Pharmacy Officer at the Massachusetts General Hospital in Boston, MA. Chris is the Chair of the Partners Healthcare Chief Pharmacy Officers Council and works to move pharmacy strategic initiatives forward at the Partners system-level.

Kevin Frankowski

(919) 966-1659

Research in the Frankowski lab uses synthetic chemistry to develop new approaches for the treatment of unmet medical needs. Our current efforts focus on programs to treat metastatic cancer, hepatitis C virus infection and the development of chemical tools for studying dopamine and sigma receptors.

Amber Frick

(919) 962-5495

Amber Frick, Pharm.D., Ph.D., is an assistant professor with the Division of Pharmacotherapy and Experimental Therapeutics. Her main responsibilities at the School are to develop an expertise in the implementation and assessment of new approaches to and best practices in teaching while also taking part in collaborative teaching activities.

Stephen Frye

(919) 843-5486

CO-MENTORING DOCTORAL STUDENTS The Frye lab focuses on chemical biology of chromatin regulation with an emphasis on proteins that bind methylated lysine, and collaborative oncology drug discovery with faculty in the Lineberger Cancer Center. Students in the Frye lab develop expertise in synthetic chemistry, biophysical techniques, assay development, structure-based drug design and medicinal chemistry.

Dong Fu

(919) 962-0089

Dong Fu, Ph.D., is an assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics. His research interests are liver cell biology and hepatic pharmacology, especially, the cellular processes and the mechanisms that are related to hepatocyte polarization, hepatic transporters trafficking, bile acid signaling, drug-induced mitochondrial and hepatocellular injury and lipids metabolism in hepatocytes.

Kathryn Fuller

(984) 974-1708

Kathryn Fuller received her Bachelor of Science degree in Microbiology and Immunology from the University of Miami and Doctor of Pharmacy degree from the University of North Carolina at Chapel Hill. She later completed an Academic Fellowship in Educational Innovation at the UNC Eshelman School of Pharmacy where she helped design several course series and the first-year capstone. Fuller then completed a PGY1 pharmacy practice residency at UNC Health. Currently, she is an assistant professor at the UNC Eshelman School of Pharmacy and practices in the transitions of care clinic at UNC Family Medicine.

Tashani Gaskins

(919) 962-8434

Tashani J. Gaskins, D.B.A., is the research and operations project director for the Center for Medication Optimization (CMO) in the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. Gaskins joined the school in September 2016. In her current role, she manages center operations, coordinates research efforts, and manages external collaborations. Gaskins’ prior experience includes serving as the chief financial officer and chief operating officer for a privately funded behavioral health and wellness center. Her professional interests include improving healthcare and increasing access to healthcare for underserved populations. Gaskins received her Doctorate in Business Administration with a focus in Entrepreneurship in 2020 from Walden University. She also has a Master’s in Business Administration (2006) and a Bachelor’s in Business Administration (2003) with a focus in Human Resources from the University of North Carolina Greensboro.

Jacqueline Gerhart

(919) 966-5914

Jackie Gerhart, MS, is a graduate student in the Division of Pharmacotherapy and Experimental Therapeutics.  Prior to starting the graduate program at UNC, she studied biomedical engineering at Drexel University and worked in drug development at GlaxoSmithKline. Her research interests include the application of modeling and simulation techniques to characterize pharmacokinetics and clinical pharmacology.

Lida Ghazanfari

(919) 962-1011

Dr. Ghazanfari earned her PhD from Amirkabir University of Technology in 2014. She also holds MSc and BSc degrees in biomedical engineering from Amirkabir University of Technology. Ghazanfari joined the laboratory of Alexander Kabanov in 2016. Ghazanfari’s research interests span a wide range of topics in theranostic platforms with a direct impact on cancer nanotechnology, including intelligent control of nano-bio interfaces to develop new nano-based therapies for prevention/treatment of cancer, innovation in multifunctional nanocomposite integration of nano-sized drug formulations, efficient stimuli and remotely actuated drug delivery systems. She is currently working under the guidance of Drs. Jonathan Serody and Alexander Kabanov.

Alexander Golbraikh

(919) 966-3459

Alexander Golbraikh’s research is geared toward the development and application of computational methods for drug discovery and design. Revolutionary development of information and communication technologies during the last few decades has dramatically changed our capabilities of collecting and accessing all sorts of data.

Daniel Gonzalez

(919) 966-9984

Daniel Gonzalez, Pharm.D., Ph.D., is an associate professor in the Division of Pharmacotherapy and Experimental Therapeutics. His research interests include pediatric clinical pharmacology and the application of mathematical modeling and simulation techniques to characterize the pharmacokinetics and pharmacodynamics of drugs, guide dosage selection, and improve drug safety in children.

Ricardo Gonzalez

(919) 966-5993

Ricardo Gonzalez is a graduate student in the Division of Pharmacotherapy and Experimental Therapeutics. His research interests include pharmacogenomics in oncology, genetic etiology of cancer drug response and synergistic/antagonistic effects of combination chemotherapy.

Robert Granko

(919) 966-5746

Robert P. Granko, PharmD, MBA, FASHP is the Mid-Atlantic Director of Field Pharmacy Services at Premier Inc. Dr. Granko is the former Director of Pharmacy at The Moses H. Cone Memorial Hospital in Greensboro, NC, a 536-bed community teaching and flagship hospital for the Cone Health Network. Dr. Granko founded and directed the Cone Health Network Health-System Pharmacy Administration/MS PGY-2 Residency Program and maintains an academic appointment at the University of North Carolina Eshelman School of Pharmacy.

Lauren Haar

Our projects focus on investigating the role that refined spatial and temporal control of intracellular signaling cascades can play in the progression of cardiovascular injury. We use a research strategy involving plasmid and optogenetic protein engineering, high content screening, high resolution microscopy and physiologically based cell analysis. With this approach we hope to uncover new targets for therapeutic development by better defining signaling cascades that drive cardiovascular disease response.

Faustina Thanh-Lan X Hahn

(919) 962-5382

Faustina Hahn, PharmD, is a postdoctoral research associate with CIPhER at the UNC Eshelman School of Pharmacy. She received her Doctor of Pharmacy from UNC Eshelman School of Pharmacy in 2019. Her research interests include diversity and inclusion, the intersection between diversity, inclusion, and mental health, and interprofessional education.

Olivia Hammill

(919) 962-0097

Olivia joined the team in the Office of Curricular and Student Affairs in the UNC Eshelman School of Pharmacy in 2017. She serves the assistant director for recruitment and admissions, leading recruitment and admissions initiatives for both the graduate and PharmD programs. Her background is in higher education, public affairs, and communications. A double alumna of Carolina, Olivia enjoys cheering on the Heels and running.

Kelli Hammond

(919) 966-9183

The Innocenti lab works with data and specimens from many clinical trials. Kelli is the translation research coordinator for the lab which involves project planning, organizing team conference calls, as well as sample and data management.

Zongchao Han

The Zongchao Han, Ph.D., M.D., laboratory is interested in developing gene therapies for retinal diseases. Han’s lab is particularly interested in understanding the gene expression patterns that are regulated by the cis-regulatory elements. Another interest of the Han laboratory is to produce a multifunctional NP carrier for specific and efficient gene/drug targeting.

Patrick Hanafin

(919) 966-1120

Patrick Hanafin, B.S., is a graduate student in the Division of Pharmacotherapy and Experimental Therapeutics. His research interests include pharmacometrics, clinical pharmacology, and quantitative systems pharmacology.

Suzanne C Harris

Suzanne Harris is an assistant professor in the Division of Practice Advancement and Clinical Education and the Director of Well-being and Resiliency at the UNC Eshelman School of Pharmacy. She also serves as a board-certified clinical pharmacy practitioner in psychiatry at UNC Medical Center, where she is involved with psychiatric medication management for patients with psychosomatic disorders and serves as a preceptor for pharmacy students and residents.

Emily B Harrison

(919) 843-8227

Emily Harrison, Ph.D., joined UNC in 2016 after receiving her B.S. from the University of Nebraska at Omaha and her Ph.D. in neuroscience at the University of Nebraska Medical Center. Harrison studied the role of microRNAs in traumatic brain injury under the guidance of Howard Fox, Ph.D. Her current research focus, under the guidance of Chad Pecot, M.D., is uncovering novel miRNA regulators of cancer metastasis and exploring therapeutic strategies for microRNA delivery and inhibition.

Nate Hathaway

(919) 445-9327

ACCEPTING DOCTORAL STUDENTS The Hathaway lab was established at UNC with a founding idea that the group could make a contribution to understanding dynamic epigenetic processes by using unique chemical biology approaches they pioneered. Through the combination of protein bioengineering, synthetic organic chemistry, and mammalian cell-based model systems, they have created platforms that use chemically tethered enzymatic recruitment to specific chromatin loci to produce a host of mechanistic insights. The Hathaway group also has drug discovery programs to identify new small molecules that inhibit disease relevant epigenetic pathways both for research purposes and as potential future therapeutics.

Meghan Hauser

(919) 962-7328

Meghan Hauser serves as the Director of Industry and Foundation Relations for Pharmaceutical Sciences in the Eshelman School of Pharmacy and is a member of the Corporate and Foundation Relations team in University Advancement. In this role, she focuses on building strong partnerships with corporations and foundations and aligning their interests with the research, programs, and institutional priorities within the School. She also stewards and advances the School’s relationship with these constituents.

Inbal Hazkani BenDror

(919) 962-1011

Hazkani BenDror joined UNC in 2018. She received her M.D. from Ben-Gurion University of the Negev Medical School in 2006. She combines surgical experience in Otolaryngology with an interest in biomedical nanotechnology. She is currently working under the guidance of Drs. Andrew Wang and Alexander Kabanov on surgical implications for nanotechnology and head and neck cancer immunotherapy.

Erin Heinzen

(919) 843-5981

The Heinzen Lab focuses on the genetic and genomic basis of epilepsy disorders, including analyses of the role of germline mutations, somatic mutations, and how regulation of the cellular transcriptome influences the risk and presentation of seizures. In collaboration with a number of investigators in neurology, neuropathology, and neurosurgery, my group is to studies the role of somatic mutations in epilepsy and other neurological diseases.

Jerry Heneghan

(919) 962-8144

Jerry Heneghan, M.B.A., joined the UNC Eshelman School of Pharmacy as a professor of the practice and as director of the Center for Innovation in Pharmacy Simulation. He holds an M.B.A. from the Fuqua School of Business at Duke University, and a B.S. in Engineering from the U.S. Military Academy. Heneghan specializes in the development of medical simulation technology.

Colleen Higgins

(919) 966-2812

Colleen studied public health at the UNC Gillings School of Global Public Health focusing on economic evaluation, health care modeling, and international health issues. She worked previously for a German economics firm modeling the social impact of innovative medicines. Before that she studied Philosophy and German in San Diego, California, and was an English teacher in Seoul, South Korea.

Shawn D Hingtgen

(919) 537-3827

Due to their expansive utility, stem cell-based therapies hold the potential to redefine therapeutic approaches and provide cures for many terminal diseases. In the Hingtgen lab, we seek to harness the potential of stem cells to develop new and better methods for treating terminal cancers, including brain cancer. We use an integrative approach that begins with creating specially designed targeted therapeutic proteins.

Henry Ho

(919) 962-5551

Henry Ho, B.A. in Chemistry, is a lab assistant in the Brouwer laboratory in the Division of Pharmacotherapy and Experimental Therapeutics. His research interests include drug transport and disposition, regulation of transporters, and chemical biology.

Paavo Honkakoski

Paavo Honkakoski, Ph.D., a global expert on nuclear receptors and professor of Biopharmacy at the School of Pharmacy and Faculty of Health Sciences at the University of Eastern Finland, is a visiting scholar and the recipient of the Nannerl O. Keohane Distinguished Visiting Professorship (August 1, 2019 – December 31, 2020). He will work on the regulation of drug metabolizing enzymes and transport proteins, nuclear receptor biology, and assessment of the absorption, distribution, metabolism, excretion and toxicological properties of medications.